CancerLinQ® Unites Oncology Care Leaders to Strengthen Resources and Improve Patient Care

CancerLinQ® Unites Oncology Care Leaders to Strengthen Resources and Improve Patient Care

This past year, CancerLinQ LLC, a wholly-owned nonprofit of ASCO, announced several new collaborations with a variety of organizations in cancer care. This multidisciplinary coalition of leaders is committed to accelerating the ability to gather new insights from the CancerLinQ® platform. Together, the expert guidance from these partners from the public, private, and nonprofit sectors can work to improve quality, efficiency, and value for the entire cancer care continuum.

Over the last year, CancerLinQ® announced official partnerships with a number of organizations, including the American Society for Radiation Oncology, the American Academy of Physician Assistants, the College of American Pathologists, Cancer Informatics for Cancer Centers, the Hematology/Oncology Pharmacy Association, the Society of Gynecologic Oncology, and the Oncology Nursing Society.

These societies will comprise the CancerLinQ® Oncology Leadership Council, a body of thought leaders and oncology-affiliated experts that advises the CancerLinQ® Board of Governors. These partners will also educate their members about the use, purpose, and benefits of the CancerLinQ® network and platform, allowing its professional members an opportunity to participate and use CancerLinQ® where relevant, similar to other collaborating organizations.

They will also have access to de-identified data from CancerLinQ® and CancerLinQ Discovery for research and learning purposes. CancerLinQ Discovery, which launched in November 2016, will provide curated, de-identified sets of clinical data for those in the oncology field to use to create new clinical knowledge and improve patient outcomes. The sets will be pulled from the growing CancerLinQ® database. AstraZeneca is the founding enterprise partner for CancerLinQ Discovery.

In addition, ASCO is collaborating with the National Comprehensive Cancer Network® (NCCN®) to link the NCCN Drugs & Biologics Compendium® to CancerLinQ®. This resource will support CancerLinQ® physicians and provide evidence-based guidance regarding the appropriate use of drugs and biologics in patients with cancer.

Two exciting new efforts—one with the U.S. Food and Drug Administration and one with the National Cancer Institute’s Surveillance, Epidemiology, and End Results program—are also underway. For more information, read the Sunday issue of the ASCO Daily News.

Learn more information on the latest collaborations.

CancerLinQ® is a powerful platform containing vast amounts of real-world cancer information. This national initiative will allow cancer care providers to improve the quality and value of care by analyzing millions of medical records from patients with cancer, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines.

Nearly 90 practices and institutions across 40 states and the District of Columbia, representing thousands of physicians, have signed agreements to participate in CancerLinQ®. These practices range from small community practices to large integrated delivery networks and academic medical centers. The practices also use a wide range of electronic health record systems because CancerLinQ® can interface with virtually any electronic system.

CancerLinQ® is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. CancerLinQ® and CancerLinQ Discoveryare projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ®, please visit us online.